Liver Toxicity After Switching or Simplifying to Nevirapine-Based Therapy Is Not Related to CD4 Cell Counts: Results of the TOSCANA Study

REFERENCES

• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008; 1–139. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adultand-AdolescentGL.pdf. Accessed September 21,2009.
   Google Scholar
• Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13(14):1873–1880.
   PubMed Web of Science ®Google Scholar
• Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169–177.
   PubMed Web of Science ®Google Scholar
• Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171–S176.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to pro-tease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
   PubMed Web of Science ®Google Scholar
• Moyle G. The Assessing Patients' Preferred Treatments (APPT-1) study. Int J STD AIDS. 2003;14(Suppl 1):34–36.
   PubMed Web of Science ®Google Scholar
• Harris M. Efficacy and durability of nevirapine in antiretro-viral-experienced patients. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S53–S58.
   PubMed Web of Science ®Google Scholar
• European Public Assessment Report for Viramune. Revi-sion 25. Published June 11, 2009. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/viramune/viramune.htm. Accessed September 21,2009.
   Google Scholar
• Viramune (nevirapine). Boxed warning update Feb 2004. MedWatch. The FDA Safety Information and Adverse Event Reporting Program. Available at: http//:www.fda.gov/medwatch/SAFETY/2004safety04.htm#viramune.
   Google Scholar
• Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S21–S33.
   PubMed Web of Science ®Google Scholar
• van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the effi-cacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS. 2005;19(5):463–471.
   PubMed Web of Science ®Google Scholar
• Storfer S, Leith J, Robinson P, Piliero P, Hall D. Analysis of hepatic events within the 2NN study: Controlling for geographic region and CD4+ cell count at initiation of nevirapine therapy. European AIDS Clinical Society (EACS) Meeting. Dublin, Ireland 2005. PE 9.6/2.
   Google Scholar
• De Lazzari E, Leon A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med. 2008;9(4):221–226.
   PubMed Web of Science ®Google Scholar
• Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitor in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349(11):1036–1046.
   PubMed Web of Science ®Google Scholar
• Wolf E, Koegl C, Theobald T. Nevirapine-associated hepa-totoxicity: No increased risk for females or high CD4 count in a single centre HIV cohort. In: Program and abstracts of the 46th ICAAC; September 27–30, 2006; San Francisco, CA. Abstract H–1063.
   Google Scholar
• Manfredi R, Calza L. Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. AIDS. 2006;20(17):2233–2236.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Staszewski S, Weber R, et al. Risk of dis-continuation of nevirapine due to toxicities in antiret-roviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther. 2007;12(3):325–333.
   PubMed Web of Science ®Google Scholar
• Wit FW, Kesselring AM, Gras L, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis. 2008;46(6):933–940.
   PubMed Web of Science ®Google Scholar
• Peters P, Stringer J, McConnell M, et al. CD4 cell count 250 cells/mm3 does not predict rash-associated hepato-toxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya. In: Program and abstracts from the 16th Conference on Retroviruses and Opportu-nistic Infections; February 8–11, 2009; Montreal, Canada. Abstract 986.
   Google Scholar
• van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417)1253–1263.
   Web of Science ®Google Scholar
• Chu K, Boulle A, Ford N, et al. Nevirapine-induced hepatotoxicity: Incidence, determinants, and associated mortality in a primary care ART program, South Africa. In: Program and abstracts from the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Canada. Abstract 603.
   Google Scholar
• Mocroft A, Rockstroh J, Soriano V, et al. Are specific antiretrovirals associated with an increased risk of dis-continuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005;10(7):779–790.
   PubMed Web of Science ®Google Scholar
• Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15(10):1261–1268.
   PubMed Web of Science ®Google Scholar